secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0001193125-22-052050
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Teva EVP Global R&D Dr. Hafrun Fridriksdottir to depart, search underway
------------------------------------------------------------------------

- Dr. Hafrun Fridriksdottir, EVP Global R&D, is leaving Teva.
- She will remain in role until June 20, 2022 to assist transition.
- Teva has initiated a search for the next head of Global R&D.
- No successor has been named as of the filing date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312522052050/0001193125-22-052050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312522052050/d268582d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-052050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer